Report overview
This report contains market size and forecasts of Recombinant Human Follicle-stimulating Hormone in Global, including the following market information:
Global Recombinant Human Follicle-stimulating Hormone Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global top five companies in 2022 (%)
The global Recombinant Human Follicle-stimulating Hormone market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
75IU Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Recombinant Human Follicle-stimulating Hormone include Merck, Ferring, Livzon, Gedeon Richter, GenSci, Teva, ChangChun High & New Technology, ABL and Scripps Laboratories, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We has surveyed the Recombinant Human Follicle-stimulating Hormone companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Recombinant Human Follicle-stimulating Hormone Market, by Type, 2018-2023, 2023-2030 ($ millions)
Global Recombinant Human Follicle-stimulating Hormone Market Segment Percentages, by Type, 2022 (%)
75IU
150IU
Others
Global Recombinant Human Follicle-stimulating Hormone Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global Recombinant Human Follicle-stimulating Hormone Market Segment Percentages, by Application, 2022 (%)
Infertility Treatment
Assisted Reproductive Technology
Global Recombinant Human Follicle-stimulating Hormone Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global Recombinant Human Follicle-stimulating Hormone Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Recombinant Human Follicle-stimulating Hormone revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Recombinant Human Follicle-stimulating Hormone revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Ferring
Livzon
Gedeon Richter
GenSci
Teva
ChangChun High & New Technology
ABL
Scripps Laboratories
Alphamab Oncology
Hunan Jingfeng Pharmaceutical
Qilu Pharmaceutical
Beijing SL Pharmaceutical
